AbD Serotec Opens New U.S. Office in Research Triangle Region
August 4, 2006
AbD Serotec – A division of MorphoSys of Munich, Germany, has opened new U.S. offices in the technology cluster Research Triangle Region near Raleigh, North Carolina. Guests of Honor at the recent Opening Ceremony were Dr. Simon E. Moroney, Chief Executive Officer of MorphoSys AG, and Tim Bernard, Head of Sales for AbD Serotec.
AbD Serotec is the new MorphoSys division focused on supplying antibodies and antibody services to the research and diagnostic markets, and combines the offerings of Serotec, Biogenesis, Oxford Biotechnology, and Antibodies by Design. The division has sales offices in the U.K., U.S., Germany, France, and Norway, and production facilities in the U.K. and Germany. The new 5,542 square foot facility will provide additional space for new staff, increased stock levels for the expanded product range, and the expansion of sales for the custom monoclonal antibodies formerly provided by Antibodies by Design.
AbD Serotec now offers U.S. customers a product portfolio of more than 8,000 research antibodies and reagents for use in research areas such as Immunology, Neurology, Cell Biology, and Histology, plus the opportunity to receive custom monoclonal antibodies in just 8 weeks using the MorphoSys HuCAL® technology.
“The U.S. is the world’s largest market for antibodies as research tools which we offer through our business unit AbD Serotec. We are pleased to establish a larger U.S. support center for this segment,“ commented Dr. Simon E. Moroney, Chief Executive Officer of MorphoSys AG. “The Research Triangle Region offers an excellent infrastructure and a significant concentration of life science companies plus first-class research institutes and universities.”
“We are pleased to have found a new facility here with the space for the growth we are expecting in the coming years,” said Tim Bernard, Head of Sales for AbD Serotec. “Our expanded product range and new HuCAL® monoclonal antibody technology from MorphoSys is very exciting and provides us with many new sales opportunities.”
About MorphoSys’ AbD Serotec:
MorphoSys develops and applies innovative technologies for the production of synthetic antibodies which accelerate drug discovery and target characterization. Founded in 1992, the Company’s proprietary Human Combinatorial Antibody Library (HuCAL®) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (New Jersey/USA), Centocor Inc. (Malvern, Pennsylvania/USA), Daiichi Sankyo & Co., Ltd. (Tokyo/Japan), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Merck & Co., Inc. (Whitehouse Station, New Jersey/USA), Novartis AG (Basel, Switzerland), Novoplant GmbH (Gatersleben, Germany), OncoMed Pharmaceuticals Inc. (Mountain View, C USA), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany), Schering-Plough (Palo Alto/USA), Shionogi & Co., Ltd. (Osaka/Japan), Xoma Ltd. (Berkeley, California/USA) and others. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit.
For further information, please visit the corporate website at: morphosys.com; information on MorphoSys’s AbD Serotec is available at: ab-direct.com.
Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, “forward-looking statements” for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company’s proprietary rights and other factors described in the prospectus relating to the company’s recent public offering.
For more information, please contact AbD Serotec:
morphosys.com |
